Hypertension enhances A β -induced neurovascular dysfunction, promotes β -secretase activity, and leads to amyloidogenic processing of APP

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 1, 2016, Pages 241-252

  Faraco, Giuseppe ^a   Park, Laibaik ^a   Zhou, Ping ^a   Luo, Wenjie ^a,b   Paul, Steven M ^a,b   Anrather, Josef ^a   Iadecola, Costantino ^a  

^a FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

endothelium dependent vasodilatation; functional hyperemia; Tg2576; TgSwDI; CTF

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN II; BETA SECRETASE; REACTIVE OXYGEN METABOLITE; SECRETASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; CEREBROVASCULAR DISEASE; CHO CELL LINE; DEOXYCORTICOSTERONE-SALT INDUCED HYPERTENSION; ELEVATED BLOOD PRESSURE; ENZYME ACTIVITY; FEMALE; HYPERTENSION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; VASCULAR AMYLOIDOSIS; VIBRISSA; WESTERN BLOTTING; ALZHEIMER DISEASE; ANIMAL; BLOOD; BLOOD PRESSURE; BRAIN CIRCULATION; C57BL MOUSE; CEREBRAL AMYLOID ANGIOPATHY; COMPLICATION; CRICETULUS; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CEREBRAL AMYLOID ANGIOPATHY; CEREBROVASCULAR CIRCULATION; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; HYPERTENSION; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 84951569058     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.79     Document Type: Article

References (40)

1. Huang Y and Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012; 148: 1204-1222
2. Iadecola C. The pathobiology of vascular dementia. Neuron 2013; 80: 844-866
3. Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 2013; 70: 440-444
4. Wierenga CE, Hays CC and Zlatar ZZ. Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease. J Alzheimers Dis 2014; 42: S411-S419
5. McDade E, Kim A, James J, Sheu LK, Kuan DC, Minhas D, et al. Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. Neurology 2014; 83: 710-717
6. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015; 85: 296-302
7. Yaffe K, Vittinghoff E, Pletcher MJ, Hoang TD, Launer LJ, Whitmer R, et al. Early adult to midlife cardiovascular risk factors and cognitive function. Circulation 2014; 129: 1560-1567
8. Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 2672-2713
9. Larson EB, Yaffe K and Langa KM. New insights into the dementia epidemic. N Engl J Med 2013; 369: 2275-2277
10. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-360
11. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-738
12. Hamel E. The cerebral circulation: function and dysfunction in Alzheimer's disease. J Cardiovasc Pharmacol 2015; 65: 317-324
13. Deschaintre Y, Richard F, Leys D and Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009; 73: 674-680
14. Valenti R, Pantoni L and Markus HS. Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review. BMC Med 2014; 12: 160
15. Faraco G and Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension 2013; 62: 810-817
16. Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R and Park DC. Risk factors for betaamyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 2013; 70: 600-606
17. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 2009; 72: 1720-1726
18. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, et al. Hypertension induces brain betaamyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 2012; 60: 188-197
19. Cifuentes D, Poittevin M, Dere E, Broqueres-You D, Bonnin P, Benessiano J, et al. Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease. Hypertension 2015; 65: 218-224
20. Faraco G, Moraga A, Moore J, Anrather J, Pickel VM and Iadecola C. Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation. Hypertension 2013; 62: 759-766
21. Capone C, Faraco G, Peterson JR, Coleman C, Anrather J, Milner TA, et al. Central cardiovascular circuits contribute to the neurovascular dysfunction in angiotensin II hypertension. J Neurosci 2012; 32: 4878-4886
22. Park L, Zhou P, Koizumi K, El JS, Previti ML, Van Nostrand WE, et al. Brain and circulating levels of Abeta1-40 differentially contribute to vasomotor dysfunction in the mouse brain. Stroke 2013; 44: 198-204
23. Grobe JL, Buehrer BA, Hilzendeger AM, Liu X, Davis DR, Xu D, et al. Angiotensinergic signaling in the brain mediates metabolic effects of deoxycorticosterone (DOCA)-salt in C57 mice. Hypertension 2011; 57: 600-607
24. Park L, Wang G, Zhou P, Zhou J, Pitstick R, Previti ML, et al. Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc Natl Acad Sci USA 2011; 108: 5063-5068
25. Park L, Zhou J, Zhou P, Pistick R, El JS, Younkin L, et al. Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc Natl Acad Sci USA 2013; 110: 3089-3094
26. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539
27. Bettayeb K, Oumata N, Zhang Y, Luo W, Bustos V, Galons H, et al. Small-molecule inducers of Abeta-42 peptide production share a common mechanism of action. FASEB J 2012; 26: 5115-5123
28. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 2004; 95: 1019-1026
29. Capone C, Faraco G, Park L, Cao X, Davisson RL and Iadecola C. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol 2011; 300: H397-H407
30. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH and Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001; 21: 372-381
31. De SB, Vassar R and Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010; 6: 99-107
32. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, et al. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J 2010; 29: 3408-3420
33. Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, Matsui T, Jinnouchi Y, et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005; 70: 137-141
34. Hasegawa K, Yamaguchi I, Omata S, Gejyo F and Naiki H. Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 1999; 38: 15514-15521
35. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 1999; 2: 157-161
36. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006; 103: 18727-18732
37. Csiszar A, Tucsek Z, Toth P, Sosnowska D, Gautam T, Koller A, et al. Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in beta-amyloid generation and Alzheimer's disease. Am J Physiol Heart Circ Physiol 2013; 305: H1120-H1130
38. Reudelhuber TL. Where hypertension happens. J Clin Invest 2013; 123: 1934-196
39. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med 2011; 17: 1402-1409
40. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402.